ReviewFuture oncology (London, England)2012
Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis.
Review in Future oncology (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Targeting Bcl-xL to eliminate chemotherapy-induced tumor dormancy and prevent breast cancer metastasis.British journal of cancer · 2026Article
- Dual Functions of T Lymphocytes in Breast Carcinoma: From Immune Protection to Orchestrating Tumor Progression and Metastasis.Cancers · 2023Review
- Role of Circ-ITCH Gene Polymorphisms and Its Expression in Breast Cancer Susceptibility and Prognosis.Diagnostics (Basel, Switzerland) · 2023Article
- Uncovering the roles of microRNAs/lncRNAs in characterising breast cancer subtypes and prognosis.BMC bioinformatics · 2021Article
- Identification of Diagnostic Markers for Breast Cancer Based on Differential Gene Expression and Pathway Network.Frontiers in cell and developmental biology · 2021Article
- Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process.Oncotarget · 2018Article
- Prognostic genes of breast cancer revealed by gene co-expression network analysis.Oncology letters · 2017Article
- Intra- and interspecies gene expression models for predicting drug response in canine osteosarcoma.BMC bioinformatics · 2016Article
- Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.Molecular aspects of medicine · 2014Review
- BTG1 underexpression is an independent prognostic marker in esophageal squamous cell carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- The expression of BTG1 is downregulated in nasopharyngeal carcinoma and possibly associated with tumour metastasis.Molecular biology reports · 2014Article
- Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens.Cancer prevention research (Philadelphia, Pa.) · 2014Article
- BTG1 expression correlates with the pathogenesis and progression of breast carcinomas.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Hyaluronan and RHAMM in wound repair and the "cancerization" of stromal tissues.BioMed research international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Breast cancer mortality is usually due to distant recurrence of cancer at an advanced stage of the disease rather than from primary cancer. Therefore, prediction of breast cancer recurrence at the time of diagnosis could lead to advances in personalized treatment of cancer patients in order to prevent risk of recurrence. Two prognostic biomarkers that are currently being used in clinical practice are a 70-gene MammaPrint signature and a 21-gene Oncotype DX panel. These assays generate relative risks of recurrence, but they do not provide a 'yes' or 'no' answer about recurrence in a given patient. These tests include genes that are involved in the cell cycle, invasion, metastasis and angiogenesis related to breast cancer. Emerging evidence suggests that a signature of genes involved in tumor-immune interactions may provide a more accurate prognostic tool. This paper reviews recent advances in the discovery of prognostic biomarkers for breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.